These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Akman A; Yilmaz E; Mutlu H; Ozdogan M Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094 [TBL] [Abstract][Full Text] [Related]
3. Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris. Okamoto K; Maeda H; Shiga T; Shiga M; Dabanaka K; Hanazaki K; Kobayashi M World J Gastroenterol; 2015 Mar; 21(12):3746-9. PubMed ID: 25834345 [TBL] [Abstract][Full Text] [Related]
4. [Cetuximab. A monoclonal antibody against the EGF receptor]. Wasielewski S Med Monatsschr Pharm; 2004 Sep; 27(9):292-4. PubMed ID: 15490614 [No Abstract] [Full Text] [Related]
5. The biological properties of cetuximab. Vincenzi B; Schiavon G; Silletta M; Santini D; Tonini G Crit Rev Oncol Hematol; 2008 Nov; 68(2):93-106. PubMed ID: 18676156 [TBL] [Abstract][Full Text] [Related]
6. Cetuximab in advanced non-small cell lung cancer. Govindan R Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231 [TBL] [Abstract][Full Text] [Related]
9. Papulo-pustular eruption during cetuximab treatment. Satta R; Cuccuru MA; Pirodda C; Cottoni F G Ital Dermatol Venereol; 2008 Feb; 143(1):87-8. PubMed ID: 18833056 [No Abstract] [Full Text] [Related]
15. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Bernier J Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142 [TBL] [Abstract][Full Text] [Related]
16. Cetuximab, its clinical use and future perspectives. Rivera F; Vega-Villegas ME; López-Brea MF Anticancer Drugs; 2008 Feb; 19(2):99-113. PubMed ID: 18176106 [TBL] [Abstract][Full Text] [Related]
17. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. Lin WL; Lin WC; Yang JY; Chang YC; Ho HC; Yang LC; Yang CH; Hung SI; Chung WH J Clin Oncol; 2008 Jun; 26(16):2779-80. PubMed ID: 18509187 [No Abstract] [Full Text] [Related]
18. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Wong SF Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976 [TBL] [Abstract][Full Text] [Related]
19. Potential of ErbB4 antibodies for cancer therapy. Hollmén M; Elenius K Future Oncol; 2010 Jan; 6(1):37-53. PubMed ID: 20021208 [TBL] [Abstract][Full Text] [Related]
20. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]